10-K: Viking Therapeutics Advances Obesity, NASH Pipeline

Viking Therapeutics reports significant clinical progress for its metabolic and endocrine disorder pipeline, including positive Phase 2 results for oral and subcutaneous VK2735 in obesity and VK2809 in NASH/MASH, alongside Phase 3 initiations.

Summary

• VK2735 (subcutaneous): Phase 1 completed March 2023. Phase 2 VENTURE study initiated September 2023, with enrollment completed October 2023. In February 2024, patients receiving weekly doses demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 14.7% from baseline and up to 13.1% relative to placebo. Phase 3 VANQUISH-1 and VANQUISH-2 studies were initiated in June 2025, and enrollment for VANQUISH-1 was completed in November 2025.
• VK2735 (oral): A Phase 1 clinical study was initiated in March 2023. In March 2024, 28-day MAD study results showed dose-dependent reductions in mean body weight from baseline, ranging up to approximately 5.3%. A Phase 2 clinical trial was initiated in January 2025, with positive top-line results announced in August 2025, demonstrating statistically significant reductions in body weight of up to 12.2% from baseline compared to 1.3% with placebo. Phase 3 oral dosing studies are expected to initiate in the third quarter of 2026.
• VK2735 (maintenance dosing): An exploratory Phase 1 maintenance dosing study was initiated in October 2025, with enrollment completed in January 2026, to explore various dosing regimens to sustain weight loss.
• DACRA program: A new, internally developed Dual Amylin and Calcitonin Receptor Agonist (DACRA) program for obesity was announced in 2024, with plans to file an Investigational New Drug (IND) application in the first quarter of 2026.
• VK2809 (NASH/MASH): The VOYAGE study (Phase 2b) was initiated in November 2019, with patient enrollment completed in January 2023. In May 2023, the study achieved its primary endpoint with statistically significant reductions in liver fat content. In June 2024, positive 52-week histologic data showed up to 75% of patients achieving NASH/MASH resolution with no worsening of fibrosis (compared to 29% for placebo, p=0.0001) and up to 57% achieving 1-stage improvement in fibrosis with no worsening of NASH/MASH (compared to 34% for placebo, p<0.05).
• VK0214 (X-ALD): A Phase 1b clinical trial was initiated in June 2021. Results announced in October 2024 showed VK0214 to be safe and well-tolerated, with significant reductions in plasma levels of very long chain fatty acids (VLCFAs) and other lipids. The company intends to pursue partnering or licensing opportunities for VK0214.
• VK5211 (hip fracture): Positive top-line results from a Phase 2 clinical trial were announced in November 2017, demonstrating statistically significant, dose-dependent increases in lean body mass. The company intends to pursue partnering or licensing opportunities for VK5211.
• Manufacturing: In March 2025, multi-year manufacturing agreements were entered into with CordenPharma for VK2735 API and finished product supply, securing dedicated capacity for multiple metric tons of API, 100 million autoinjectors, 100 million vial and syringe products, and over one billion oral tablets annually. Prepayments will be made from 2026 to 2028, fully credited against future orders.
• Financials: The company reported a net loss of $359.6 million for the year ended December 31, 2025, compared to $109.9 million in 2024. Research and development expenses increased to $345.0 million in 2025 from $101.6 million in 2024. Cash, cash equivalents, and short-term investments totaled $705.7 million as of December 31, 2025.
• Legal Proceedings: In May 2025, the ITC affirmed the substantial majority of the Chief Administrative Law Judge's determinations in favor of Viking Therapeutics against Ascletis Defendants for trade secret misappropriation, including monetary and non-monetary sanctions. Both parties filed notices of appeal in September 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the strong clinical progress and manufacturing agreements, which de-risk future commercialization. However, the significant increase in net loss and R&D expenses, coupled with the need for future capital raises, introduces financial caution.

Positives

• VK2735 subcutaneous demonstrated statistically significant reductions in mean body weight up to 14.7% from baseline and 13.1% relative to placebo after 13 weeks in the Phase 2 VENTURE study.
• VK2735 oral achieved statistically significant reductions in body weight up to 12.2% from baseline compared to 1.3% with placebo after 13 weeks in the Phase 2 VENTURE-Oral Dosing trial.
• VK2809 showed positive 52-week histologic data in the VOYAGE study, with up to 75% of patients achieving NASH/MASH resolution with no worsening of fibrosis (p=0.0001 vs. placebo) and up to 57% achieving 1-stage improvement in fibrosis (p<0.05 vs. placebo).
• VK0214 demonstrated encouraging safety and tolerability, along with significant reductions in plasma VLCFAs and other lipids, in its Phase 1b clinical trial for X-ALD.
• Secured broad, multi-year manufacturing agreements with CordenPharma for VK2735, ensuring dedicated capacity for API and finished product supply, including 100 million autoinjectors and over one billion oral tablets annually.
• Initiation of Phase 3 clinical studies (VANQUISH-1 and VANQUISH-2) for subcutaneous VK2735 and planned Phase 3 oral dosing studies for VK2735 in Q3 2026, indicating significant pipeline advancement.
• The International Trade Commission (ITC) affirmed the misappropriation of trade secrets by Ascletis Defendants, resulting in favorable determinations and sanctions for Viking Therapeutics.
• The company maintains a strong cash, cash equivalents, and short-term investments balance of $705.7 million as of December 31, 2025, which is believed to be sufficient to fund operations through at least Q1 2027.

Negatives

• Net loss significantly increased to $359.6 million in 2025 from $109.9 million in 2024, indicating a substantial rise in operational expenses.
• Research and development expenses more than tripled to $345.0 million in 2025 from $101.6 million in 2024, reflecting a higher cash burn rate.
• The company has incurred operating losses and negative cash flows from operations since its inception and has not generated any revenue to date.
• Cash, cash equivalents, and short-term investments decreased from $902.6 million in 2024 to $705.7 million in 2025, despite a significant capital raise in March 2024.
• The company is substantially dependent on technologies licensed from Ligand, and termination of the Master License Agreement could materially and adversely affect the business.
• The ongoing appeals in the trade secret litigation with Ascletis Defendants prolong legal costs and introduce continued uncertainty.
• The company expects to continue to incur significant operating losses for the foreseeable future and will need to raise additional capital, which may cause dilution to existing stockholders.

Risks

• The company is a clinical-stage company with a limited operating history and is expected to incur significant operating losses during the next stages of corporate development.
• Substantial dependence on technologies licensed from Ligand Pharmaceuticals Incorporated, with a risk of losing the license or termination of the Master License Agreement.
• Dependence on the success of one or more current drug candidates, with no certainty of regulatory approval or commercialization.
• Development of drug candidates may not produce favorable results, leading to an inability to commercialize these products.
• Delays in the commencement or completion of clinical trials could result in increased costs and delay the ability to establish strategic collaborations.
• Reliance on third parties to conduct preclinical studies and clinical trials and perform other tasks, with risks of non-performance, missed deadlines, or non-compliance with regulatory requirements.
• Competitors may have drug candidates that are approved faster, marketed more effectively, are better tolerated, have a more favorable safety profile, or are demonstrated to be more effective.
• Unstable market and economic conditions may have serious adverse consequences on the business and financial condition.
• Inability to obtain or maintain necessary rights to drug candidates through acquisitions and in-licenses.
• Failure to comply with obligations in in-license agreements could lead to loss of intellectual property rights.
• Drug candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization.
• Efforts to discover drug candidates beyond current ones may not succeed, and any recommended candidates may not begin clinical trials.
• Expenditure of limited resources on a specific product candidate or indication may lead to failure to capitalize on more profitable opportunities.
• Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.
• Delays in the enrollment of patients in clinical trials could delay or prevent necessary regulatory approvals.
• Drug candidates are subject to extensive, costly, and time-consuming regulation under the FDA, EMA, or comparable foreign authorities.
• Even if drug candidates receive regulatory approval, they may still face future development and regulatory difficulties, including restrictions on use or post-approval studies.
• The FDA, EMA, and comparable foreign authorities actively enforce laws and regulations prohibiting the promotion of off-label uses.
• Subject to a multitude of manufacturing risks, including product loss, contamination, equipment failure, and supply disruptions.
• Complete reliance on third parties to manufacture preclinical and clinical drug supplies, with risks if those third parties fail to provide sufficient quantities or acceptable quality.
• Contract manufacturers may not continue to meet regulatory requirements (cGMP).
• Any collaboration arrangement entered into in the future may not be successful.
• Inability to develop own commercial organization or enter into agreements with third parties to sell and market drug candidates.
• Commercial success depends upon market acceptance among physicians, patients, healthcare payors, and the medical community.
• Failure to obtain and sustain an adequate level of reimbursement for potential products by third-party payors.
• Current and future legislation (e.g., ACA, IRA) may increase the difficulty and cost of commercializing drug candidates and affect prices.
• Disruptions at the FDA, SEC, and other government agencies caused by funding shortages, government shutdowns, or global health concerns could negatively impact business operations and regulatory interactions.
• Subject to fraud and abuse and similar laws and regulations, and a failure to comply could harm the business.
• Business may be impacted by actions of the current U.S. administration, including executive orders, policies, new legislation, and judicial decisions.
• Compliance with global privacy and data security requirements (e.g., GDPR, CCPA, HIPAA, Bulk Transfer Rule) could result in additional costs and liabilities.
• Subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• Governments outside the United States tend to impose strict price controls, which may adversely affect revenue.
• Failure to retain current members of senior management and scientific personnel, or to attract and keep additional key personnel.
• Need to increase the size of the organization and may not successfully manage growth.
• Exposed to product liability, non-clinical, and clinical liability risks.
• Research and development activities involve the use of hazardous materials, subjecting the company to regulation, costs, and potential liabilities.
• Reliance significantly on information technology, and any failure, inadequacy, interruption, or security lapse could harm business operations.
• Artificial intelligence presents risks and challenges that can impact the business, including security risks to confidential information and an uncertain regulatory environment.
• Employees and consultants may engage in misconduct or other improper activities.
• Business disruptions such as natural disasters or geopolitical conflicts could seriously harm future revenues and financial condition.
• Engaging in strategic transactions could impact liquidity, increase expenses, and distract management.
• Employment agreements with officers and certain other employees may require severance benefits in connection with a change in control.
• Unstable market and economic conditions may have serious adverse consequences on the business and financial condition.
• Subject to economic, political, regulatory, and other risks associated with international operations.
• International operations may subject the company to greater than anticipated tax liabilities.
• Inability to protect proprietary or licensed technology in the marketplace.
• Licensed patents or future owned patents may be challenged, narrowed, invalidated, or circumvented.
• Infringement of the intellectual property rights of others may prevent or delay drug development efforts.
• Claims or lawsuits relating to infringement of intellectual property rights will be costly and time-consuming.
• Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents.
• Inability to protect intellectual property rights throughout the world.
• Inability to adequately prevent unauthorized disclosure of trade secrets and other proprietary information.
• Subject to claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Subject to claims challenging the inventorship of licensed patents and other intellectual property.
• Failure to obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation extending patent terms.
• The market price of common stock may be highly volatile.
• An active trading market for common stock may not be sustained.
• Management owns a significant percentage of stock and can exert significant control.
• Internal control over financial reporting may not meet Sarbanes-Oxley Act standards.
• Operating as a public company incurs significantly increased costs and requires substantial management time for compliance initiatives.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about the business, stock price and trading volume could decline.
• Sales of a substantial number of shares of common stock by existing stockholders or future issuances could cause the stock price to fall.
• Management has broad discretion over the use of proceeds from prior financings and available cash.
• Risk of securities class action litigation.
• Ability to use net operating loss carryforwards may be subject to certain limitations.
• Changes in tax laws could adversely affect the business and financial condition.
• No dividends expected on common stock, so any returns would be limited to stock appreciation.
• Provisions in charter documents and Delaware law could make it more difficult or expensive for a third party to acquire the company or change its board of directors or current management.
• Amended and restated bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings.
• The timing and amount of any repurchases under the stock repurchase program are subject to a number of uncertainties.

Future Outlook

The company expects to initiate Phase 3 oral dosing studies for VK2735 in the third quarter of 2026 and plans to file an Investigational New Drug (IND) application for its Dual Amylin and Calcitonin Receptor Agonist (DACRA) program in the first quarter of 2026. It intends to pursue partnering or licensing opportunities for VK0214 and VK5211 prior to conducting additional clinical studies. The company believes its current cash, cash equivalents, and short-term investments are sufficient to fund operations through at least the first quarter of 2027, but anticipates continued operating losses and increased research and development expenses, necessitating additional capital raises in the future.

Management Comments

• Our intent is to pursue partnering or licensing opportunities for VK0214 prior to conducting additional clinical studies.
• Our intent is to continue to pursue partnering or licensing opportunities for VK5211 prior to conducting additional clinical studies.

Industry Context

StockSavvy.ai notes that Viking Therapeutics is operating in highly competitive and rapidly evolving biopharmaceutical sectors, particularly obesity and NASH/MASH. The positive clinical data for VK2735 positions it as a strong contender against established players like Novo Nordisk (Semaglutide, Liraglutide) and Eli Lilly (Tirzepatide) in the lucrative obesity market, and its oral formulation could offer a significant competitive advantage. For NASH/MASH, VK2809's positive histologic data is notable, especially given Resmetirom (Rezdiffra) from Madrigal Pharmaceuticals is the only approved therapy, suggesting a potential for VK2809 to capture market share if approved. The DACRA program and X-ALD candidate VK0214 also target areas with unmet medical needs, indicating a diversified pipeline strategy.

Comparison to Industry Standards

• Obesity (VK2735): VK2735 subcutaneous achieved up to 14.7% mean body weight reduction from baseline (13.1% vs placebo) after 13 weeks. Oral VK2735 achieved up to 12.2% reduction (vs 1.3% placebo) after 13 weeks. This compares favorably to existing GLP-1/GIP agonists: Eli Lilly's Zepbound (tirzepatide) showed up to 22.5% weight loss at 72 weeks in SURMOUNT-1, and Novo Nordisk's Wegovy (semaglutide) showed 15% weight loss at 68 weeks in STEP 1. While Viking's 13-week data is promising, longer-term Phase 3 data will be crucial for direct comparison to the sustained weight loss seen with Zepbound and Wegovy. The oral formulation's efficacy is particularly competitive against other oral GLP-1s in development.
• NASH/MASH (VK2809): VK2809 demonstrated up to 75% NASH/MASH resolution with no worsening of fibrosis (vs 29% placebo) and up to 57% 1-stage fibrosis improvement (vs 34% placebo) at 52 weeks. Madrigal Pharmaceuticals' Rezdiffra (resmetirom), the only FDA-approved NASH drug, showed 25.9% NASH resolution with no worsening of fibrosis (vs 13.5% placebo) and 24.2% fibrosis improvement by at least one stage with no worsening of NASH (vs 14.2% placebo) at 52 weeks in its MAESTRO-NASH trial. VK2809's reported efficacy appears numerically superior to Rezdiffra's in both NASH resolution and fibrosis improvement, suggesting a potentially best-in-class profile if confirmed in Phase 3.
• X-ALD (VK0214): There are currently no marketed therapies for the treatment of X-ALD in the U.S., except for allogeneic hematopoietic stem cell (HSC) therapy and gene therapy (elivaldogene autotemcel from bluebird bio, Inc.) for the most severe form, CALD. VK0214's positive Phase 1b data showing VLCFA reductions addresses a significant unmet medical need, particularly for the adrenomyeloneuropathy (AMN) form of X-ALD where current treatments are ineffective.

Management Changes

Corporate Governance

Legal Proceedings

• In December 2022, filed suit against Ascletis Bioscience Co., Ltd. and affiliates in the Southern District of California, San Diego division, alleging violation of the Defend Trade Secrets Act, California Uniform Trade Secrets Act, breach of contract, breach of implied covenant of good faith and fair dealing, and tortious interference with contract.
• Filed a related action against the same Ascletis Defendants in the International Trade Commission (ITC) for unlawful and unfair methods of competition.
• On October 3, 2024, the ITC's Chief Administrative Law Judge issued a Notice of determination that the Ascletis Defendants misappropriated trade secrets and engaged in discovery misconduct, warranting monetary and non-monetary sanctions.
• On May 29, 2025, the full ITC affirmed the substantial majority of the Chief Administrative Law Judge's determinations in favor of Viking Therapeutics, including monetary and non-monetary sanctions.
• On September 26, 2025, the Ascletis Defendants filed a notice of appeal in the United States Court of Appeals for the Federal Circuit, challenging the ITC's affirmance.
• On September 26, 2025, Viking Therapeutics also filed a notice of appeal in the United States Court of Appeals for the Federal Circuit, challenging a narrow portion of the ITC's decision.

Related Party Transactions

• In May 2014, entered into a Master License Agreement with Ligand Pharmaceuticals, Inc., granting exclusive worldwide rights to VK2809, VK0214, VK5211, VK0612, EPOR, and DGAT-1 programs.
• Issued 3,655,964 shares of common stock to Ligand, with an estimated aggregate value of $29.2 million, as partial consideration for the license.
• Agreed to pay Ligand up to an aggregate of $1.54 billion in development, regulatory, and sales milestone payments for Licensed Products.
• Will pay tiered percentage royalties in the low-to-upper single digits on aggregate annual worldwide net sales of Licensed Products to Ligand.
• The Management Rights Letter with Ligand terminated on March 28, 2023, when Ligand ceased to beneficially own at least 7.5% of the company's outstanding voting stock.

Stakeholder Impact

• Shareholders: Face potential for dilution from future equity raises, stock price volatility due to clinical trial outcomes and market conditions, impact from ongoing legal proceedings, and no expected dividends.
• Employees: Anticipated increase in staffing, potential for employee turnover influenced by broader economic trends, and continued incentive through stock-based compensation.
• Customers/Patients: Potential for new, effective therapies for obesity, NASH/MASH, and X-ALD if drug candidates achieve regulatory approval, addressing significant unmet medical needs.
• Suppliers/Manufacturers: Multi-year manufacturing agreements with CordenPharma for VK2735 secure dedicated capacity, indicating stable future business for this key partner, though reliance on third-party manufacturers carries inherent risks.
• Creditors: A strong cash position of $705.7 million provides liquidity, but sustained operating losses and high R&D expenditures suggest an ongoing need for capital, which could influence future credit terms.

Next Steps

• Initiate Phase 3 Oral dosing studies for VK2735 in the third quarter of 2026.
• File an Investigational New Drug (IND) application for the DACRA program in the first quarter of 2026.
• Pursue partnering or licensing opportunities for VK0214 prior to conducting additional clinical studies.
• Continue to pursue partnering or licensing opportunities for VK5211 prior to conducting additional clinical studies.
• Vigorously pursue all legal remedies in the ongoing appeals of the trade secret litigation against Ascletis Defendants.
• Expand and enhance operational, financial, and management systems to support future growth.
• Hire, train, retain, manage, and motivate additional employees.
• Develop a comprehensive compliance program to adhere to healthcare fraud and abuse laws and regulations.
• Monitor and develop contingency plans to address disruptions from geopolitical conflicts and economic instability.
• Evaluate the impact of recently issued accounting pronouncements (ASU 2025-04, ASU 2024-03) on consolidated financial statements.

Key Dates

Recommendation

The company has demonstrated strong clinical progress with multiple drug candidates, particularly VK2735 in obesity and VK2809 in NASH/MASH, which show promising efficacy and tolerability, potentially positioning them favorably against competitors. The initiation of Phase 3 trials and securing manufacturing capacity are significant de-risking steps. However, the substantial increase in net loss and R&D expenses, coupled with the stated need for future capital raises, indicates a high cash burn and potential for further dilution. The ongoing legal appeals also add a layer of uncertainty. Given the promising pipeline but also the significant financial outlay and inherent risks of clinical development, a "Hold" recommendation is appropriate for investors to monitor Phase 3 outcomes and financial management.

Keywords

Biopharmaceutical, Metabolic Disorders, Obesity, NASH, MASH, X-ALD, GLP-1, GIP, TR Beta Agonist, SARM, Clinical Trials, Phase 3, Phase 2, Drug Development, VK2735, VK2809, VK0214, VK5211, CordenPharma, SEC Filing, 10-K, Biotechnology, Pharmaceutical, Weight Loss, Fibrosis, Trade Secrets